Sitravatinib is an orally bioavailable, receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Upon administration, sitravatinib binds to and inhibits the activity of several RTKs including hepatocyte growth factor receptor (HGFR; c-Met; MET), tyrosine-protein kinase receptor UFO (AXL receptor tyrosine kinase; AXL), mast/stem cell growth factor receptor (SCFR; c-kit; KIT), the receptor tyrosine kinase MER, discoidin domain receptor 2 (DDR2), vascular endothelial growth factor receptor (VEGFR) types 1 (VEGFR-1; FLT1), 2 (VEGFR-2; KDR; Flk-1) and 3 (VEGFR-3), members of the platelet-derived growth factor receptor (PDGFR) family, RET (rearranged during transfection), tropomyosin-related kinases (TRK) and members of the ephrin (Eph) family of receptor tyrosine kinases. This may result in both the inhibition of signal transduction pathways mediated by these RTKs and the reduction of tumor cell proliferation in cancer cell types that overexpress these RTKs.
Science-backed PDE/ADE, OEL & OEB derivation by certified toxicologists with ex-agency experts -
Sitravatinib
Drug Overview
What is Sitravatinib?
To derive PDE/ADE, OEL, and OEB values, Masuu Global follows a scientifically justified, risk-based toxicological assessment approach in accordance with internationally recognized guidelines and industry best practices that are widely accepted by regulatory authorities, including European Medicines Agency (EMA), Pharmaceutical Inspection Co-operation Scheme (PIC/S), and Agência Nacional de Vigilância Sanitária (ANVISA).
Request Your Assessment
Add this compound to your inquiry list and our team will follow up with full documentation, pricing, and licensing terms.
View Inquiry List →Full OEL derivation · ADE/PDE value · Control band assignment · All cited references · EMA / ICH Q9 compliance
Regulatory Framework
Assessment Methodology
Masuu Global follows a scientifically justified, risk-based toxicological approach aligned with internationally recognized guidelines accepted by EMA, PIC/S, and ANVISA.
EMA – Guideline on Setting Health-Based Exposure Limits (HBELs)
Provides the framework for establishing scientifically justified PDE/ADE values for use in shared manufacturing facilities.
PIC/S – Shared Facilities and Contamination Control Guidance
Supports the application of HBEL-based approaches for cross-contamination prevention and cleaning validation.
ICH Q9 – Quality Risk Management
Provides a structured methodology for risk identification, assessment, control, communication, and review.
ICH M7 – Assessment and Control of DNA-Reactive (Mutagenic) Impurities (where applicable)
Applied for compounds with potential mutagenic or genotoxic concerns.
Risk-Based Toxicological Assessment
Comprehensive evaluation of available toxicological and pharmacological data, including NOAEL, LOAEL, BMDL, pharmacological potency, carcinogenicity, reproductive and developmental toxicity, sensitization potential, and target organ toxicity.
Weight-of-Evidence (WoE) Approach
Integration and critical review of all relevant data sources, including non-clinical studies, clinical studies, human exposure data, pharmacological information, post-marketing safety data, and structure–activity relationship (SAR/QSAR) assessments.
How We Work
Report Preparation Process
Every assessment moves through a rigorous five-stage workflow — from data gathering to regulatory-ready delivery.
Comprehensive Data Review
Assessment of pharmacology, toxicology, clinical data, literature, and available regulatory information.
Scientific Evaluation
Identification of critical endpoints and selection of appropriate exposure limits.
PDE / HBEL Derivation
Transparent and scientifically justified calculations aligned with global toxicological principles.
Ex-Agency Expert Review (Our Differentiator)
Reports are reviewed with an ex-agency perspective, bringing regulatory expectations, inspection readiness, and practical implementation into every assessment.
Final Report Delivery
Regulatory-ready reports with scientific rationale, calculations, and clear recommendations by certified toxicologists (ERT, UKRT and DABT).
Ex-Agency Advantage
Why Masuu Global?
Our ex-agency toxicologists bring a practical regulatory perspective that transforms how assessments are built, reviewed, and defended.
Regulatory expectation–driven assessments aligned with how authorities actually evaluate submissions.
Inspection-ready reports — scientifically defensible and audit-prepared from day one.
Faster review cycles with direct decision support from certified toxicologists (ERT, UKRT, DABT).
Practical implementation recommendations that translate science into actionable contamination control.
Reduced internal effort — offload complex assessments without sacrificing quality or defensibility.
Global reach across PDE/ADE, HBEL, OEL, OEB, cleaning validation, and impurity assessments.
Ready to request your assessment?
Add this compound to your inquiry list, or browse our full database of 3,000+ molecules.
Frequently Asked Questions
Sitravatinib is a named chemical or pharmaceutical-related substance. Its precise classification, grade, and intended use should be confirmed from the applicable technical documentation rather than inferred from the name alone. A toxicological assessment should evaluate reliable evidence for the specific material and consider its manufacturing and handling context, with assumptions and data gaps clearly documented.
A PDE or ADE sets a health-based limit on daily exposure to (2R,4S)-2-Ethyl-6-(Trifluoromethyl)-1,2,3,4-Tetrahydroquinoline-4-Amine from residual carryover. Manufacturers use it in cross-contamination risk assessments and cleaning validation when the compound is processed in shared equipment or facilities. Whether a report is required depends on how it is used and on applicable regulatory expectations.
A toxicological report for Sitravatinib should explain the evidence reviewed, the rationale for selecting relevant endpoints, the approach used to address uncertainty, and the resulting recommendations. It should distinguish established information from assumptions and data gaps. Masuu Global reports present scientific rationale, calculations, and clear recommendations prepared by certified toxicologists, with the assessment aligned to relevant guidance and the available evidence.
The assessment of Sitravatinib should consider reliable evidence for the specific substance, including repeat-dose toxicity, genotoxicity, reproductive and developmental endpoints, and pharmacological effects where relevant. The evaluator should identify the critical effect, assess study quality and relevance, and document data gaps. Conclusions should remain proportionate to the evidence rather than assume unsupported hazards or safety.
The physical form and handling conditions of Sitravatinib, such as powder, granulated material, solution, or a formulation, can influence how exposure may occur during manufacturing. The assessment should consider tasks that could generate dust, droplets, or contact, together with containment and engineering controls. Physical form does not replace toxicological hazard evaluation, but it helps translate the health-based assessment into practical workplace controls.
An OEL is derived by reviewing the toxicological and occupational health evidence, identifying the critical effect, and applying a recognized assessment methodology. The final value should come with a documented rationale, clearly stated units, and the exposure duration it applies to, so it can be used confidently in workplace risk assessment.
An OEB places (2R,4S)-2-Ethyl-6-(Trifluoromethyl)-1,2,3,4-Tetrahydroquinoline-4-Amine in a hazard category using a defined banding framework and the available toxicological evidence. Criteria and numerical ranges differ between frameworks, so the report should identify the system used. The band then guides the level of containment and handling controls suited to the compound.
An occupational exposure band for Sitravatinib can support preliminary hazard communication and control selection when a formal occupational exposure limit is unavailable or when a banding framework is used internally. However, an OEB is not automatically equivalent to a substance-specific OEL. The basis, uncertainty, and intended use of the band should be documented, and appropriate exposure controls should still be applied.
An OEL report for Sitravatinib can document the scientific rationale, relevant evidence, assessment approach, and conclusions used to support occupational exposure management. It can help occupational hygiene and manufacturing teams connect hazard evaluation with proportionate controls. The report should make assumptions and limitations clear, and its recommendations should be applied with process-specific exposure assessment and appropriate workplace practices.
A toxicological assessment of Sitravatinib helps identify relevant health hazards and provides a scientific basis for considering exposure limits and workplace precautions. Its findings can inform containment design, task procedures, exposure monitoring, personal protective equipment, and training as appropriate. Controls should reflect actual operations and exposure pathways, and the assessment should be used as part of a broader occupational hygiene program.
Masuu Global follows a scientifically justified, risk-based approach aligned with internationally recognized guidance accepted by regulators, including the EMA guideline on health-based exposure limits, PIC/S guidance on shared facilities and contamination control, ICH Q9 quality risk management, and ICH M7 where applicable.
Use the Request Your Assessment option on this page and add (2R,4S)-2-Ethyl-6-(Trifluoromethyl)-1,2,3,4-Tetrahydroquinoline-4-Amine to your inquiry list. The Masuu Global team will follow up with full documentation, pricing, and licensing terms. Mention your intended use and market so the scope of the report can be confirmed.
